MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MYX - MAYNE PHARMA GROUP LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.39
Index: ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.39
Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$6.75
18 Apr |
OPEN $6.65 |
HIGH $6.77 |
105,398 LOW $6.60 |
0.090| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -385.1 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 54.4 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 183.6 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 760.4 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -43.1 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -172.86 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -52.93 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -51.27 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -24.88 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -52.93 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -22.56 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -96.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 14 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 33 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 48 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 229 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.58 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 219.6 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 119.61 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 157 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 213 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 16 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MYX STOCK CHART
FNArena News on MYX
| 1 |
Rudi’s View: Healthcare Under The ScannerMar 13 2024 - Rudi's View |
| 2 |
In Case You Missed It – BC Extra Upgrades & Downgrades – 08-03-24Mar 08 2024 - Weekly Reports |
| 3 |
Australian Broker Call *Extra* Edition – Mar 07, 2024Mar 07 2024 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Mar 05, 2024Mar 05 2024 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – Dec 14, 2023Dec 14 2023 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
| 2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
| 3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
| 4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
| 5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
| 6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |